Washington Tests on humans will begin this fall to see if a promising new vaccine can stop and even reverse the effects of Alzheimer's disease.
The vaccine, called AN-1792, has already proven safe for humans and somewhat successful in mice. The new tests involving 375 people in the United States and Europe will determine whether it is effective in combating premature senility and memory loss.
The vaccine tries to get the body's own immune system to come up with antibodies to the brain plaque, called beta amyloid, that is seen in large amounts in Alzheimer's patients. Researchers aren't sure if it is the cause or result of Alzheimer's but lean toward thinking it is a cause.